Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 9, 2018Blood AdvancesOpen Access

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJames L. RubensteinUniversity of California, San FranciscoHGHuimin GengUniversity of California, San FranciscoEFEleanor J. FraserUniversity of California, San Francisco

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rubenstein et al. (2018) studied this question.

synapsesocial.com/papers/6a71ec2e87f9210571286536https://doi.org/10.1182/bloodadvances.2017014845
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma2015 · 32 citations
  2. 2Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma2009 · 644 citations
  3. 3Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses2010 · 28 citations
  4. 4Immunosuppressive and Anti-inflammatory Properties of Interleukin 101995 · 398 citations
  5. 5IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection2008 · 154 citations